Spyre Therapeutics, Inc.
SYRE
$16.67
$0.784.91%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 17.99% | 20.47% | 18.44% | -77.74% | 11.45% |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -118.52% | -47.62% | -71.63% | 409.24% | -51.49% |
| Change in Net Operating Assets | -1,491.73% | -105.26% | 4.32% | 135.50% | -939.50% |
| Cash from Operations | -13.58% | -10.20% | -26.44% | 52.74% | -118.09% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 118,129.51% | 99.96% | -499.03% | 135.46% | -14.82% |
| Cash from Investing | 129,604.92% | 99.96% | -499.03% | 135.46% | -14.82% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 118.21% | -99.85% | 1,627.56% | 2,542.02% | -88.72% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -62.96% | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 100.00% | 36.17% | -321.79% | -- | 100.00% |
| Cash from Financing | 484.80% | -99.94% | 1,665.27% | 3,450.00% | -99.79% |
| Foreign Exchange rate Adjustments | -- | -- | -193.75% | -- | 100.00% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 181.03% | -329.39% | -31.68% | 114.32% | -571.87% |